Supernus Pharmaceuticals will report its quarterly results this Tuesday after market hours. Last quarter, the specialty pharmaceutical company posted revenues of $207.7 million, up 38.6% year on year, beating analyst expectations, though it missed on EPS estimates. For the upcoming report, analysts expect revenue growth of 24.3% year on year, an acceleration from the 5.6% increase in the same quarter last year. The company has a history of exceeding Wall Street expectations, and analyst estimates have remained largely unchanged over the past 30 days. Supernus shares are down 5.5% over the last month, trading at $45.01, compared to an average analyst price target of $63.50.
Supernus Pharmaceuticals IncEarnings report upcoming; past results mixed and stock down, but analyst estimates unchanged.